ETFs with NPSP as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|3.89%||PowerShares Dynamic Biotech &Genome (PBE)||+7.17 (31.88%)|
|3.31%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+23.99 (27.77%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
NPS is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. We incorporated in Utah in 1986 and reincorporated in Delaware in 1992. Our lead product, Gattex® 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved by the U.S. Food and Drug Administration (FDA) in December 2012 for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. We are also developing Natpara® (rhPTH[1-84]) for the treatment of adult hypoparathyroidism. We have met with FDA to discuss our Human Factors/Usability testing of the Natpara injection pen device. The final study will be initiated in March 2013 with results expected in the second quarter of 2013. We continue to work toward submitting our U.S. Biologics License Application (BLA) for Natpara. ... More ...